RxDoctor Payments Data

Jennifer Chao, MD

Cardiovascular Disease · Great Neck, NYNPI 1417299033

Payments from drug & device makers

$1,232in general payments, 2019–2025

Across 37 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$213
  • Novartis$169
  • Pfizer$122
  • Boehringer Ingelheim$118
  • AbbVie$105
  • Merck$105
  • plus $399 from 6 others

What the payments were for

  • Food & beverage$1,232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen12$213
Novartis8$169
Pfizer1$122
Boehringer Ingelheim1$118
AbbVie1$105
Merck1$105
E.r. Squibb & Sons, L.L.C.3$100
Medtronic1$100
Johnson & Johnson4$65
AstraZeneca1$59
Novo Nordisk3$53
Althera Pharmaceuticals LLC1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,232 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$398,859
Medicare patients
682
Services billed
4,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$264,564
JardianceEmpagliflozin137$188,062
OzempicSemaglutide80$135,246
XareltoRivaroxaban101$111,225
MounjaroTirzepatide62$97,144
EntrestoSacubitril/Valsartan74$94,934
FarxigaDapagliflozin Propanediol58$75,879
Repatha SureclickEvolocumab58$62,405
TrulicityDulaglutide40$49,459
JanuviaSitagliptin Phosphate30$35,666
Praluent PenAlirocumab34$26,423
MultaqDronedarone Hcl12$20,755
VascepaIcosapent Ethyl22$12,530
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$6,679
Metoprolol Succinate342$6,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$264,564197 claims
Boehringer IngelheimJardiance$118$188,062137 claims
Novo NordiskOzempic$53$135,24680 claims
Johnson & JohnsonXarelto$65$111,225101 claims
NovartisEntresto$169$94,93474 claims
AstraZenecaFarxiga$59$75,87958 claims
MerckJanuvia$105$35,66630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →